https://www.selleckchem.com/EGFR(HER).html Exhaled breath test is a typical disease monitoring method for replacing of blood and urine samples that may create discomfort for patients. To monitor exhaled breath markers, gas biomedical sensors have undergone rapid progresses for non-invasive and point-of-care diagnostic devices. Among gas sensors, metal oxide-based biomedical gas sensors have received remarkable attentions owing to their unique properties, such as high sensitivity, simple fabrication, miniaturization, portability, and real-time monitoring. Herein, we reviewed the recent advances in chemoresistive metal oxide-based gas sensors with ZnO, SnO2, and In2O3 as sensing materials for monitoring a range of exhaled breath markers (i.e., NO, H2, H2S, acetone, isoprene, and formaldehyde). We focused on the strategies that improve the sensitivity and selectivity of metal oxide-based gas sensors. The challenges to fabricate a functional gas sensor with high sensing performance along with suggestions are outlined.The nutritional status at diagnosis, as well as weight loss during chemotherapy, are important factors for morbidity and mortality in cancer patients. They might also influence outcomes in patients with acute myeloid leukemia (AML) receiving allogeneic hematopoietic stem cell transplantation (HSCT). We evaluated the body mass index (BMI) at diagnosis, prior to HSCT, and the BMI difference (ΔBMI = BMIHSCT-BMIdiagnosis) in 662 AML patients undergoing allogeneic HSCT. Patients being obese at AML diagnosis had significantly higher nonrelapse mortality (NRM) and shorter overall survival (OS) after HSCT, but no distinct cumulative incidence of relapse than nonobese patients. Weight loss during chemotherapy (ΔBMI > -2) was a strong predictor for higher NRM and shorter OS in univariate and multivariate analyses. These results were observed across all European LeukemiaNet (ELN) 2017 risk groups but especially in patients with favorable or intermediate ELN2017 risk a